We are exploring collaborations with startups developing New Approach Methodologies (NAMs) to advance drug discovery and safety assessment. Our areas of interest include 3D cell culture, organoids, microphysiological systems (MPS), in silico toxicity assessment, Digital Organ technologies, and other innovative platforms. We are open to various forms of collaboration, including joint research and development, licensing-in, business partnerships, and investment.